ResearchFocus on the pharmaceutical and biotech industry
- Sanford Health Overview and It’s Research in Rare Diseases
Benjamin Forred, Translational Research Project Manager at Sanford Health in Sioux Falls, South Dakota, discusses his organization which is one of the largest health systems in the United States, including research into rare diseases.
- KEYNOTE-695 Study of TAVO + Keytruda in Refractory Metastatic Melanoma
Dan O’Connor, President, Director and Chief Executive Officer of OncoSec discusses the KEYNOTE-695 Study of TAVO + Keytruda in Refractory Metastatic Melanoma.
- Gene Testing for Inherited Eye Diseases
Ron Philip, Chief Commercial Officer of Spark Therapeutics, discusses gene testing for inherited eye diseases, including his company’s initative EyeWant2Know.com.
- The Role of IL-12 in Anti-PD-1 Therapies with TAVO
Dan O’Connor, President, Director and Chief Executive Officer of OncoSec discusses his company and it’s focus on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer.
- Alnylam Overview and it’s Focus on RNA Interference
Pushkal Garg, MD, Chief Medical Officer at Alnylam provides an overview of his company and its focus on RNA interference (RNAi).
- ZYN002: Being Evaluated for Fragile X Syndrome
Armando Anido, Chief Executive Officer at Zynerba Pharmaceuticals discusses his company’s lead product candidate ZYN002, a CBD gel currently being evaluated for Fragile X syndrome.
- James C. Greenwood, President of the Biotechnology Innovation Organization (BIO)
James C. Greenwood is President and CEO of the Biotechnology Innovation Organization (BIO) in Washington, DC. BIO represents 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 countries worldwide.
- Spark Therapeutics’ Pipeline Overview
Ron Philip, Chief Commercial Officer of Spark Therapeutics, discusses his company’s pipeline which is focused on a range of debilitating genetic diseases, including inherited retinal diseases (IRDs), liver-directed diseases such as hemophilia and lysosomal storage disorders and neurodegenerative diseases.
- Autism Spectrum Disorder
Armando Anido, Chief Executive Officer at Zynerba Pharmaceuticals discusses Autism Spectrum Disorder (ASD), a developmental disorder that affects communication and behavior. Zynerba is pursuing new therapeutic options for ASD and other neuropsychiatric conditions.
- Mustang Bio’s Chimeric Antigen Receptor Engineered T Cell Program
Manuel Litchman, MD, President, Chief Executive Officer at Mustang Bio discusses his company’s proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies program.